Integrated BioPharma, Inc.

As of March 31, 2026, Integrated BioPharma, Inc. carries a market capitalization of 8.41M, placing it among publicly traded companies globally. Its enterprise value stands at 5.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Integrated BioPharma, Inc. has 31.06M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.17, and the price-to-book ratio stands at 0.44.

As of March 31, 2026, Integrated BioPharma, Inc. trades at an EV/EBITDA multiple of 63.06 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.93M versus a market cap of 8.41M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Integrated BioPharma, Inc. maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Integrated BioPharma, Inc. posted a negative return on equity (ROE) of -8.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.32, reflecting losses generated across the asset base. The company generates approximately 315,366.01 in revenue per employee across its workforce of 153.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.06 indicates how many times Integrated BioPharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Integrated BioPharma, Inc. recorded 536,000.00 in income tax expense. The company reported a pretax loss of -1.12M and -1.65M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Integrated BioPharma, Inc.'s stock has declined approximately 40.88% over the past 52 weeks. The 50-day moving average sits at 0.17, while the 200-day moving average is 0.26.

Over the twelve months ended March 31, 2026, Integrated BioPharma, Inc. generated 48.25M in revenue and converted that into -1.65M in net income, yielding earnings per share of -0.05. EBITDA reached 94,000.00, while operating income came in at -1.25M.

As of March 31, 2026, Integrated BioPharma, Inc. holds 5.83M in cash and equivalents against 3.35M in total debt, resulting in a net debt position of -5.83M. Total book value stands at 18.98M, with working capital of 12.45M providing operational flexibility.

Integrated BioPharma, Inc. produced 3.03M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -201,000.00 in capital expenditures, free cash flow totaled 2.83M - equivalent to 0.09 per share.

Over the twelve months ended March 31, 2026, Integrated BioPharma, Inc. posted a gross margin of 4.64, reflecting its pricing power and cost economics. The operating margin of -2.58 and net profit margin of -3.43 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 33.62, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.40, meaning Integrated BioPharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Integrated BioPharma, Inc.'s most recent stock split took place on October 30, 1996 with a 4:1 split ratio.

As of March 31, 2026, Integrated BioPharma, Inc. has an Altman Z-Score of 1.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.